



**Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: **Daniel Press, M.D., M.C.S**

Committee: **Peripheral and Central Nervous System Drugs Advisory Committee**

Meeting Date: **June 10, 2024**

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

On June 10, 2024, the Committee will discuss biologics license application (BLA) 761248, for donanemab solution for intravenous infusion, submitted by Eli Lilly and Company, for the treatment of early symptomatic Alzheimer’s disease.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
None		
II. Other Imputed Interests		
Contracts/grants	Employer’s research funded by a competing entity, Janssen.	\$100,000 - \$200,000 per year to Beth Israel Deaconess Medical Center.

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

/S/

Signature

5/21/2024

Date